Stay updated on Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now includes a Locations section with a Quebec site; the Quebec Locations entry and the HHS Vulnerability Disclosure link were removed, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedResults status updated from No Results Posted to Results Submitted; page revision updated to v3.3.2.SummaryDifference0.1%

- Check44 days agoChange DetectedGeneral funding/operating status banner about potential data delays has been removed from the page. This removal does not affect the study details, eligibility criteria, or reported results.SummaryDifference0.4%

- Check58 days agoChange DetectedNo significant modifications to the study details page were observed; differences appear limited to layout or presentation elements. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check87 days agoChange Detected- Added a government funding lapse notice with operating status guidance and a link to cc.nih.gov and opm.gov. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

- Check94 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0: version metadata updated; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial page.